Liverpool agree to sell contract rebel for €55m
And when it comes to both incomings and outgoings, the club are not done yet.
Having added Florian Wirtz, Hugo Ekitike, Milos Kerkez, Jeremie Frimpong and Giorgi Mamardashvili to the ranks, there are plans to sign Alexander Isak as well as a centre-back later in the window.
Shop the LFC Store
LFC Kits
Shop Now
LFC x New Era
Shop Now
LFC Signed Merch
Shop Now
LFC x Titleist
Shop Now
In order to finance that kind of spend, Liverpool have been busy with sales.
Luis Diaz completed his move to Bayern Munich on Wednesday for a fee that is worth around £65m - joining Jarell Quansah, Trent Alexander-Arnold, Caoimhin Kelleher and Nat Phillips on the exit list.
But Liverpool won't stop there. There could be a sale for Ibrahima Konate - with Spanish reports now suggesting that €55m would be enough to entice Richard Hughes to sell.
Real Madrid want Konate
Konate, 26, is out of contract in less than 12 months - and a new contract hasn't been forthcoming. It means Liverpool risk losing the France defender on a free or else must accept a bid for him this summer instead.
- seeing him as a dream addition to the defensive options. And if Liverpool fail to come to an agreement over a new deal then the right thing to do could be to let him go.
€55m and he's yours
And according to Defensa Central, talks are underway between Liverpool and the 15-time European champions for Konate and the Merseysiders now have a magic number in mind.
'Liverpool has already informed Real Madrid, through several direct and indirect intermediaries, that the player is not officially for sale ... but that if anyone wants to sign him this summer and offers at least 55 million for him, they will agree to negotiate,' the report reads.
© IMAGO
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
LAUSANNE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 12, 2025, at 8:30 a.m. EDT to report financial results for the second quarter of 2025 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at The archived webcast will be available for 30 days following the call. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA and a PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker. Headquartered in Lausanne (Biopôle), Switzerland, with operations in London and New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at and follow us on LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the success of the Company's strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the expected cash runway into 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early pre-clinical research for our exatecan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS:Investors and MediaNicole RileyADC 862-926-9040 View original content to download multimedia: SOURCE ADC Therapeutics SA Sign in to access your portfolio
Yahoo
16 minutes ago
- Yahoo
Report – Liverpool Among Several Premier League Suitors For Inter Milan Top Defensive Target
Liverpool are among several Premier League clubs interested in signing Parma starlet Giovanni Leoni. According to Sportitalia via FCInterNews, the Reds' interest is serious amid rumors linking the player with Inter Milan. Giovanni Leoni is arguably the most coveted young defender in European football. Indeed, half of Serie A has already set their sights on the 18-year-old. In addition to Inter, AC Milan, Juventus, and Napoli have emerged as potential suitors. Liverpool Among Several Premier League Clubs Keen on Giovanni Leoni UDINE, ITALY – MARCH 01: Giovanni Leoni of Parma reacts at the end of the Serie A match between Udinese and Parma at Stadio Friuli on March 01, 2025 in Udine, Italy. (Photo by) Despite attracting interest from top Serie A clubs, Leoni could swap Ennio Tardini for the Premier League. While Liverpool remain the likeliest candidates to lure the teenager to England, they're not alone. Indeed, some other Premier League sides have inquired about the young gun, though talks were mostly informal. Meanwhile, Parma chiefs must be rubbing their hands. Though they had initially expected to earn around €30 million from Leoni's transfer, the price has suddenly gone up. Now, the Crusaders demand €40 million to green-light Leoni's departure, which looks inevitable.
Yahoo
16 minutes ago
- Yahoo
Opera to Announce Second Quarter 2025 Financial Results on August 19, 2025
OSLO, Norway, Aug. 5, 2025 /PRNewswire/ -- Opera Limited (NASDAQ: OPRA), one of the world's major browser developers and a leading internet consumer brand, announced today that the company's second quarter 2025 financial results will be released before the market opens on Tuesday, August 19, 2025. The earnings release will be available on our investor relations website at Management will host a conference call to discuss the second quarter 2025 financial results on the same day at 8:00 a.m. ET. Listeners may access the call by dialing the following numbers: United States: +1 800-225-9448Norway: +47 80-01-3780International: +1 203-518-9708 Confirmation Code: OPRAQ225 A live webcast of the conference call can be accessed at About OperaOpera is a user-centric and innovative software company focused on enabling the best possible internet browsing experience across all devices. Hundreds of millions use the Opera web browsers for their unique and secure features on their mobile phones and desktop computers. Founded in 1995, and headquartered in Oslo, Norway, Opera is a public company listed on the Nasdaq stock exchange under the ticker symbol "OPRA". Download the Opera web browser and access other Opera products from Learn more about Opera at View original content to download multimedia: SOURCE Opera Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
